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Background: To promote the clinical application of next-generation sequencing, it is important to obtain accurate
and consistent variants of target genomic regions at low cost. Ion Proton, the latest updated semiconductor-based
sequencing instrument from Life Technologies, is designed to provide investigators with an inexpensive platform
for human whole exome sequencing that achieves a rapid turnaround time. However, few studies have
comprehensively compared and evaluated the accuracy of variant calling between Ion Proton and Illumina
sequencing platforms such as HiSeq 2000, which is the most popular sequencing platform for the human genome.
The Ion Proton sequencer combined with the Ion TargetSeq™ Exome Enrichment Kit together make up
TargetSeq-Proton, whereas SureSelect-Hiseq is based on the Agilent SureSelect Human All Exon v4 Kit and the
HiSeq 2000 sequencer.
Results: Here, we sequenced exonic DNA from four human blood samples using both TargetSeq-Proton and
SureSelect-HiSeq. We then called variants in the exonic regions that overlapped between the two exome capture
kits (33.6 Mb). The rates of shared variant loci called by two sequencing platforms were from 68.0 to 75.3 % in
four samples, whereas the concordance of co-detected variant loci reached 99 %. Sanger sequencing validation
revealed that the validated rate of concordant single nucleotide polymorphisms (SNPs) (91.5 %) was higher than
the SNPs specific to TargetSeq-Proton (60.0 %) or specific to SureSelect-HiSeq (88.3 %). With regard to 1-bp small
insertions and deletions (InDels), the Sanger sequencing validated rates of concordant variants (100.0 %) and
SureSelect-HiSeq-specific (89.6 %) were higher than those of TargetSeq-Proton-specific (15.8 %).
Conclusions: In the sequencing of exonic regions, a combination of using of two sequencing strategies
(SureSelect-HiSeq and TargetSeq-Proton) increased the variant calling specificity for concordant variant loci and the
sensitivity for variant loci called by any one platform. However, for the sequencing of platform-specific variants, the
accuracy of variant calling by HiSeq 2000 was higher than that of Ion Proton, specifically for the InDel detection.
Moreover, the variant calling software also influences the detection of SNPs and, specifically, InDels in Ion Proton
exome sequencing.
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Whole genome sequencing (WGS) comprehensively in-
vestigates genome sequence changes such as single-nu-
cleotide variants (SNVs) [1, 2], insertions and deletions
(InDels) [3–9], chromosomal rearrangements [10, 11], and
copy-number variation [12, 13], and so on. However,
whole exome sequencing (WES) has become more popu-
lar because exons are more interpretable than other
genomic regions and because the technique allows more
samples to be analysed. Previous studies have analysed
disease loci that segregate in families [14–16], and large
disease cohorts (e.g., National Heart, Lung, and Blood
Institute), and validated their findings in WGS studies [16]
using exome sequencing technology. Other groups have
assessed the clinical application of next generation se-
quencing (NGS) by target sequencing [17–19].
With recent advances in NGS technology [2, 3, 6, 17–19],
it is now possible to sequence the whole genomic or exonic
DNA of an individual. Compared with traditional single
nucleotide polymorphism (SNP) arrays [20], WGS can
generate target DNA sequences and identify substantially
more genetic variations, thus explaining a larger fraction of
human phenotypic diversity [21].
Currently, the most widely used sequencing platform
in human genome sequencing research is the Illumina
HiSeq series of instruments (HiSeq 2000/2500), which
use highly-parallel optical sensing of polymerization re-
actions to achieve an ultra-high throughput (up to 6000
million reads per run with paired-end sequencing). Life
Technologies has also released a new version of the semi-
conductor sequencing platform, Ion Proton (Proton),
which provides researchers with an alternative sequencing
platform. Proton has a medium-throughput, cost effective-
ness and rapid turnaround time (just 4 h of sequencing
run time). Thus, Proton is an attractive means of validat-
ing the variants called in whole genomes by other sequen-
cing platforms [22], sequencing of whole exomes [23],
screening cancer-related genes in solid tumours [24], or
conducting sequencing-based clinical applications such as
prenatal diagnosis which has a strict turn-around time
requirement [25]. However, given the differences between
sequencing technologies and subsequent variant calling
pipelines applied by HiSeq 2000 and Proton, it is neces-
sary to comprehensively compare the two platforms.
Previously, the variant calling performance of the Proton
sequencer was assessed by comparing it with variants
called by HiSeq 2000 [23], Complete Genomics, and Illu-
mina SNP microarray. Another team used the Proton
sequencer to validate the whole exome variants called by
WGS on the HiSeq 2500 sequencer [22]. In the present
study, we comprehensively compared the differences be-
tween variants called by HiSeq 2000 with the Agilent
SureSelect Human All Exon v4 kit (SureSelect-HiSeq) and
Proton with the Ion TargetSeq™ Exome Enrichment kit(TargetSeq-Proton), and validated the variants by Sanger
sequencing. Our results show that there is a significant
discrepancy between SureSelect-HiSeq and TargetSeq-
Proton sequencing strategies, and provide some guidance
for analysing personal genome on different sequencing
platforms.
Results
Data summary of exome sequencing
Exonic DNA from four individual Chinese genomic DNA
samples was captured by the Ion TargetSeq™ Exome En-
richment Kit using probes of various lengths (85.1 ± 64.1),
and subsequently sequenced by the Proton sequencing
platform (Life Technologies). We obtained approximately
40× average sequence coverage on targeted regions
(Table 1). For all samples, Proton reads covered more than
90 % of the targeted region with ≥10× reads coverage.
Exonic DNA from the same four samples was separately
enriched by SureSelect Human All Exon V4 with 120 bp
probes, then sequenced on HiSeq 2000 with 2*100 bp read
lengths. We obtained ≥33× sequence coverage on targeted
regions (Table 1, Additional file 1: Figure S1), and more
than 86 % of target regions had ≥10× reads coverage.
Definition of the evaluation region
We chose the overlapping 33.6 Mb exonic regions as an
evaluation region between the Ion TargetSeq™ Exome
Enrichment Kit and the Agilent SureSelect V4 Kit. A total
of 25,446, 25,413, 25,429, and 25,080 variant loci were
detected by Proton and HiSeq 2000 in samples S1, S2, S3,
and S4, respectively (Table 2). The co-detected rates of
total variant loci were 68.0 %, 75.3 %, 71.7 % and 71.5 %,
respectively, on two sequencing platforms for four sam-
ples (Table 2). The analyses of the four samples were
consistent when evaluating the numbers and co-detection
rates of loci observed. Therefore, we randomly chose to
describe the results of sample S3 in this report.
When considering SNP loci, we evaluated the ratio of
transitions to transversions (Ti/Tv) because unusually high
or low ratios may be indicative of false positive variants.
Overall, Ti/Tv was 2.70 in the total detected SNPs of sam-
ple S3 (Additional file 2: Table S1). For concordant SNPs,
the Ti/Tv ratio was 3.05. By contrast, notable differences
were observed in the ratios of HiSeq 2000-specific (2.02)
or Proton-specific (1.93) SNPs, regardless of whether they
were novel or known in dbSNP (build 137).
Comparison of variants-detecting platforms
For sample S3, a total of 25,429 variant loci were detected
by Proton or HiSeq 2000, of which 18,222 loci were also
detected by Proton and HiSeq 2000 concurrently (Table 2).
The concordance of 18,222 co-detected variant loci
reached 99.3 % (18,087). Concordance was determined by
the loci with the same variant genotype. Among the
Table 1 Statistics of reads and alignment to reference genome for four samples’s exome sequencing on TargetSeq-Proton/
SureSelect-HiSeq platform


















S1 TargetSeq-Proton 48.2 4.5 42.9 94.1 39.8 97 94 90 79
SureSelect-HiSeq 78.3 7.8 77.4 2*100 40.0 100 97 90 71
S2 TargetSeq-Proton 62.4 6.1 55.1 97.4 51.9 98 95 93 86
SureSelect-HiSeq 79.9 7.9 79.1 2*100 45.3 100 98 91 74
S3 TargetSeq-Proton 61.3 5.5 55.3 90.9 50.3 97 94 91 84
SureSelect-HiSeq 56.8 5.6 56.2 2*100 33.4 100 96 86 63
S4 TargetSeq-Proton 53.9 5.2 49.4 96.9 49.8 97 94 91 84
SureSelect-HiSeq 59.5 5.9 58.9 2*100 36.0 100 96 87 66
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InDels were identified. Of the SNPs, 94.9 % (16,810) were
reported in dbSNP, while 92.4 % (339) of the small InDels
were also reported in this database (Table 3). Of the 5689
total variants only detected by HiSeq 2000, 95.4 % of 4897
SNPs and 90.8 % of 792 small InDels were reported in
dbSNP. However, this was true of only 80.2 % of the 1305
SNPs and 12.7 % of the 213 small InDels among the 1518
total variants specific to Proton.
We observed a notable difference in the size distribution
of InDels calling by the two sequencing platforms as well
as the percentage that had been previously reported in
dbSNP. Figure 1 shows the size distributions of both con-
cordant and platform-specific InDels. Among all concord-
ant small Indels, 49.0 % (180/367) were 1-bp, which is
similar to that of HiSeq 2000-specific (55.3 %). However,
this value was 78.4 % for Proton-specific small InDels.
Analysis of the composition and homopolymer size of
1-bp InDel loci flanking sequences showed that 1-bp
InDels called by Proton were biased toward homopoly-
mer types G and C (Additional file 3: Figure S2).
Among the discordant variant loci, the majority (n =
104) were heterozygote calls by Proton but homozygote
calls by HiSeq 2000 (Table 2). Additionally, 26 discordant
loci were homozygous calls by Proton to heterozygousTable 2 Variant loci detected by TargetSeq-Proton and SureSelect-H
Total locia Co-detected loci(%)b Concordant locic
S1 25466 17314(68.0) 17202
S2 25413 19148(75.3) 19039
S3 25429 18222(71.7) 18087
S4 25080 17937(71.5) 17808
aTotal loci: all variant loci in the overlapping regions detected by HiSeq 2000 or Ion
TargetSeq-HiSeq-specific and SureSelect-Proton-specific loci
bCo-detected loci: the variant loci co-detected by TargetSeq-HiSeq and SureSelect-P
The number in parentheses is percentage
cConcordant loci: the variant loci with the same genotype detected by between Tar
dDisconcordant loci: the loci with different variant genotype detected by between T
variant genotype is homozygotes detected by TargetSeq-Proton, but heterozygotes
analogous variant genotypecalls by HiSeq 2000. A few discordant loci consisted of
different heterozygotes (n = 4) and different homozygotes
(n = 1) co-detected by Proton and HiSeq 2000.Validation by Sanger sequencing
To validate variants called by the two sequencing plat-
forms, we PCR-amplified genomic DNA fragments con-
taining selected SNPs and small InDels, then sequenced
them. A total of 240 SNPs of all four samples were ran-
domly selected for validation: 80 HiSeq 2000-specific, 80
Proton-specific and 80 concordant SNPs. Of all 240 SNPs,
69.2 % were successfully amplified and sequenced. The
validation rate was 91.5 % for concordant SNPs, 88.3 %
for HiSeq 2000-specific and 60.0 % for Proton-specific
SNPs (Table 4).
As the small InDels biased toward 1-bp InDels (Fig. 1),
we selected 80 concordant, 80 HiSeq 2000-specific, and
80 Proton-specific 1-bp InDels for Sanger sequencing
validation. Of all 240 InDels, 63.3 % (n = 152) were
successfully amplified and sequenced. Concordant and
HiSeq 2000-specific InDels had validation rates of 100.0 %
(n = 47) and 89.6 % (n = 60), respectively (Table 4). How-
ever, the validation rate of 38 Proton-specific InDels was
only 15.8 % (n = 6).iSeq sequencing
Disconcordant loci(TargetSeq-Proton/SureSelect-HiSeq)d
Hom/Hom Hom/Het Het/Hom Het/Het
1 15 93 3
2 20 84 3
1 26 104 4
1 16 111 1
Proton sequencing, which include the Concordant, Disconcordant,
roton sequencing, which include Concordant and Disconcordant loci.
getSeq-HiSeq and SureSelect- Proton sequencing
argetSeq-Proton and SureSelect-HiSeq. Hom/Het refers to the loci whose
detected by SureSelect-HiSeq. Hom/Hom, Het/Hom and Het/Het refer to
Table 3 Pairwise comparison of variants called for four samples by TargetSeq-Proton and SureSelect-HiSeq
TargetSeq-Proton-specific(dbSNP|novel)a Concordant(dbSNP|novel) SureSelect-HiSeq-specific(dbSNP|novel)
Total SNPs InDels Total SNPs InDels Total SNPs InDels
S1 1470 (1021|449) 1274 (998|276) 196 (23|173) 17202 (16288|914) 16833 (15943|890) 369 (345|24) 6682 (6348|334) 5851 (5606|245) 831 (742|89)
S2 1432 (1018|414) 1229 (996|233) 203 (22|181) 19039 (18038|1001) 18655 (17683|972) 384 (355|29) 4833 (4533|300) 4044 (3839|205) 789 (694|95)
S3 1518 (1073|445) 1305 (1046|259) 213 (27|186) 18087 (17149|938) 17720 (16810|910) 367 (339|28) 5689 (5390|299) 4897 (4671|226) 792 (719|73)
S4 1462 (1069|393) 1326 (1051|275) 136 (18|118) 17808 (16891|917) 17409 (16521|888) 399 (370|29) 5681 (5353|328) 4922 (4674|248) 759 (679|80)
aThe numbers of parentheses refer to known or unknown variant loci in dbSNP databases
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For the Proton sequencing platform, the bwa-GATK pipe-
line were shown to call more than twice as many variants
(n = 52,117) as the Torrent Variant Caller (TVC) pipeline
(n = 19,847). Variant concordance between the two pipe-
lines was only 29.8 %. We also noted that the concordance
(1.1 %) of novel variants was much lower than that of
known variants (71.2 %). Although the concordance of
SNPs between the two pipelines was 71.6 % among all
22,496 SNPs, the InDel concordance was extremely low, at
just 1.3 % for all 32,925 InDels (Additional file 4: Table S2).
For the HiSeq 2000 sequencing platform, we also investi-
gated the differences between variants detected by bwa-
GATK and stampy-GATK pipelines. A 90.5 % concordance
rate for all 24,407 variants was observed, with the overall
concordance of novel variants (44.1 %) shown to be much
lower than that of known variants (92.4 %) (Additional
file 5: Table S3). The 92.8 % concordance of SNPs was also
higher than the 57.7 % concordance of InDels.
Validated rates of three calling pipelines which differ only
in read mapping, were also compared: bwa-se refers to bwa
mapping of HiSeq 2000 reads to the human reference with
the single-end reads mode, bwa-pe uses the paired-end readFig. 1 Distribution of size and classification of small InDel called by exome
Four classes of small InDel were defined as concordant novel, concordant
reported in dbSNP build 137. Known refers to InDels previously reported in
called by TargetSeq-Proton. b showed the size and classification of small Inmode, and stampy-se uses stampy-1.0.22 software (http://
www.well.ox.ac.uk/project-stampy) with the single-end read
mode [26]. In the sets of Sanger sequencing validated vari-
ants, the bwa-pe pipeline called 130 SNPs, which was more
than bwa-se and stampy-se, which called 127 and 114
SNPs, respectively. Additionally, the validated rate of SNPs
called by the bwa-pe pipeline (90.0 %) was higher than that
of bwa-se (86.6 %) and stampy-se (88.6 %) (Table 5).
Discussion
Following important advances in NGS technologies and
target DNA enrichment techniques [27, 28], WES is
being used to identify variants associated with disease
[15, 29–34]. However, few studies have comprehensively
investigated the accuracy of variant calling across differ-
ent sequencing platforms. This report focused on the
variants detected by Proton and HiSeq 2000 combined
with different exome enrichment kits.
Because of differences in the target regions between the
Ion TargetSeq™ Exome Enrichment Kit and SureSelect
Human All Exon V4 Kit, we considered only 33.6 Mb of
overlapping regions between the two kits and evaluated
the accuracy of three kinds of variant in four samples:sequencing on SureSelect-HiSeq and TargetSeq-Proton in sample S3.
known, specific novel and specific known. Novel refers to InDels not
dbSNP build 137. a showed the size and classification of small InDels
Dels called by SureSelect-HiSeq
Table 4 Sanger sequencing validation comparison on variant subsets of TargetSeq-Proton and SureSelect-HiSeq data calls
SureSelect-HiSeq-specific TargetSeq-Proton-specific Concordant
1-bp InDels SNPs 1-bp InDels SNPs 1-bp InDels SNPs
Validated true 89.6 %(60) 88.3 %(53) 15.8 %(6) 60.0 %(21) 100.0 %(47) 91.5 %(65)
Validated false 10.4 %(7) 11.7 %(7) 84.2 %(32) 40.0 %(14) 0.0 %(0) 8.2 %(6)
A total of 240 SNPs and 240 1-bp InDels from four samples were randomly selected for Sanger sequencing validation, with 80 loci from the set of
TargetSeq-Proton-specific, 80 from the set of SureSelect-HiSeq-specific, and 80 from the set of concordance between two platforms
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HiSeq-specific SNVs. The results showed that ~70 % of
variants were concordant and ~30 % were platform-
specific. Additionally, the validation rate of concordant
SNPs and 1-bp InDels was found to be highest, up to
91.5 % and 100.0 %, respectively, followed by SureSelect-
HiSeq-specific (88.3 % for SNPs and 89.6 % for 1-bp
InDels), then TargetSeq-Proton-specific at just 60.0 % for
SNPs and 15.8 % for 1-bp InDels (Table 4).
Parla et al. previously observed that the SeqCap EZ
Human Exome Kit (Roche NimbleGen) and SureSelect
Human All Exon Kit performed similarly in target cap-
turing and sequencing [35], whereas Chilamakuri et al.
reported that four exonic DNA enrichment kits (Nim-
bleGen SeqCap EZ, Agilent SureSelect, Illumina TruSeq
Exome, and Nextera Exome) performed well in a sys-
tematic comparison of exome database coverage, target
capturing efficiency, and GC bias [36].
In the present report, the Agilent SureSelect V4 Kit used
120-bp RNA probes with a GC content of 49.3 ± 11.1 %,
whereas the Ion TargetSeq™ Exome Enrichment Kit used
variable length DNA probes of 85.1 ± 64.1 bp with a GC
content of 48.9 ± 12.2 %. These differences may affect the
GC content of reads (Additional file 6: Table S4) and the
coverage of specific loci, which can influence variant call-
ing, although the global coverage was similar at the level
of 10× sequencing depth (Table 1, Additional file 1: Figure
S1). The notable discrepancy of variant calling between
SureSelect-HiSeq and TargetSeq-Proton sequencing plat-
forms can be explained in part by different capturing effi-
ciency of exome enrichment kits and the inadequate
sequencing depth of platform-specific loci. For example,
of 5689 SureSelect-HiSeq-specific variants in sample S3,
only 5.3 % (301) were not covered and 46.6 % (2650) were
covered at ≤10× by TargetSeq-Proton reads; among 1518
TargetSeq-Proton-specific variants, 2.1 % (32) were not
sequenced and 30.2 % (459) were sequenced at ≤10× byTable 5 Comparison of the validation rates of variants called by diff
bwa_pea variants bwa_
InDels SNPs InDel
Validated true 93.1 %(108) 90.0 %(117) 93.1 %
Validated false 6.9 %(8) 10.0 %(13) 6.9 %
Note: abwa-pe, bwa mapping with paired-end reads mode
bbwa-se, bwa mapping with single-end reads mode
cstampy-se, stampy-1.0.22 software mapping with single-end reads modethe SureSelect-HiSeq strategy. Thus, partial one platform-
specific variants can also be detected by another platform
when sequencing coverage increases.
The discrepancy mainly results from other factors such
as characters intrinsic in sequencing platforms, read align-
ment and variant calling methods. Although the detailed
InDel error rate was unavailable in our study, the Proton
sequencing platform biases InDel errors because its
underlying sequencing principle is the same as that of Ion
Torrent Personal Genome Machine (PGM). In untrimmed
bases of PGM, the error rate varies from 0.84 to 1.76 %
for insertion errors and from 0.80 to 1.07 % for deletion
errors [37]. To minimise the impact of InDel errors pro-
duced by the Proton sequencing platform, base calling
using Torrent Suite Software was performed with fairly
stringent filters. This decreased the number of variants
detected by Proton reads, as shown by the fact that several
SureSelect-HiSeq-specific validated variants were not de-
tected by TargetSeq-Proton although they were covered
by Proton reads. Compared with variants called by Tor-
rent Suite Software, about 90 % of variants (35,574)
called only by the bwa-GATK pipeline were novel small
InDels, which represents a high possibility of false posi-
tives (Additional file 4: Table S2). This shows that the
TVC pipeline, optimised to deal with varied length reads
and error profiles specific to Proton system, processed the
Proton data much better than the bwa-GATK pipeline.
Characterization of the flanking 10-bp reference regions
of the 1-bp small InDels showed that ~70 % loci were in
homopolymer regions (Additional file 7: Table S5). More-
over, HiSeq 2000 detected 1-bp InDels more sensitively
than Proton (Additional file 3: Figure S2), even in the
region with a homopolymer size of ≥10 bp. By contrast,
the homopolymer size of InDel regions detected by Proton
rarely exceeded 5. Our observation that Proton reads were
slightly biased to InDel errors occurring in homopolymer
types A and T (Additional file 8: Figure S3) was less thanerent pipelines for SureSelect-HiSeq data
seb variants stampy_sec variants
s SNPs InDels SNPs
(108) 86.6 %(110) 92.5 %(99) 88.6 %(101)
(8) 13.4 %(17) 7.5 %(8) 11.4 %(13)
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that a more accurate variant calling method should be
developed for use of the Proton platform to detect small
InDels.
As a biologically relevant and prevalent form of genetic
variation [39], more than 800,000 InDels in a diverse
population have been mapped to known genes, some of
which can be associated with genetic diseases [40, 41].
Our analysis revealed a substantial difference in the InDels
detection ability between Proton and HiSeq 2000, which
was also observed in previous studies [23]. Similarly, low
concordant InDels called by different pipelines have also
been reported previously [42]. The low validation rate of
variants specific to TargetSeq-Proton showed that Proton
has a high false positive rate of calling small InDels or
SNPs. Recently, a new open source algorithm, Scalpel, has
been developed [43]. This combines mapping, assembly,
and repeat analysis, and is coupled with a self-tuning
k-mer strategy for the sensitive and specific discovery of
InDels in exome capture data. Scalpel outperforms other
InDel calling approaches (such as GATK HaplotypeCaller
and SOAPindel [44]) for InDel discovery, particularly in
regions containing near-perfect repeats, and has the power
to detect long (≥30 bp) transmitted events as well as
enriching likely gene-disrupting InDels in autistic chil-
dren. However, it is unknown whether Scalpel is suitable
for Proton fragment reads because it was developed for
Illumina HiSeq 2000 paired-end reads.
Our comparison of different SNV calling pipelines for
HiSeq 2000 data revealed that two single-end mapping
methods for HiSeq 2000 reads slightly decreased the num-
ber and accuracy of SNPs (Table 5). This suggests that
paired-end sequencing and mapping should be performed
if possible. Our data also demonstrated that HiSeq 2000
and Proton platforms are partially complementary for
variant detection. To obtain truly comprehensive exonic
variants, WES should be performed on different platforms
with deep paired-end coverage.
Conclusions
We detected SNPs and small InDels of four whole exomes
using Torrent Suite Software 3.6.2 for TargetSeq-Proton
data and using bwa-GATK for SureSelect-HiSeq data. We
observed a notable discrepancy in variant calling between
HiSeq 2000 and Proton sequencing platforms. A more
comprehensive set of variants could be obtained by com-
bining deep sequencing from HiSeq 2000 and Proton.
Among the different subsets of variants, the Sanger
sequencing validation of concordant variants was higher
than that of variants specific to SureSelect-HiSeq or
TargetSeq-Proton sequencing strategies. For sequencing
platform-specific variants, SureSelect-HiSeq achieved a
higher level of accuracy in variant calling than TargetSeq-
Proton, specifically for InDel detection. The combinationof deep paired-end sequencing on different sequencing
platforms, alongside the development and application of
multiple variant calling tools, will effectively maximise the
sensitivity and specificity of variant detection in biomed-
ical applications.
Methods
Sample collection and genomic DNA preparation
This study was approved by Beijing Institute of Genomics
Institutional Review Board for Human Investigation under
the HHS Federal Wide Assurance of Compliance Number
00014534 and IRB registration number IORG0005863.
Written informed consent for participation was obtained from
the participants (>18 years age) prior to sample collection.
Blood samples were collected from four individuals
and genomic DNA was extracted using alkaline lysis and
ethanol precipitation with the QIAamp DNA Blood Kits
(Qiagen, Valencia, CA). The pure high molecular weight
genomic DNA samples were quality-checked on agarose
gels and quantified using a micro-volume spectropho-
tometer (NanoDrop 1000; Thermo Fisher Scientific Inc.,
West Palm Beach, FL).
Ion TargetSeq exome enrichment and Proton Sequencing
For each sample, 3 μg high-quality genomic DNA was
used to prepare the Ion TargetSeq-Exome 50 Mb capture
library. Randomly fragmented genomic DNA underwent
adapters-ligation, nick-repairing, and purification prior to
size selection according to the manufacturer’s instructions
(Ion TargetSeq Guide; Life Technologies, Carlsbad, CA).
Size selection was conducted using the iBase unit Power
System and the E-Gel SizeSelect 2 % Agarose Gel (Life
Technologies). Library DNA was obtained and amplified
according to the Ion TargetSeq Guide. The amplified
product was cleaned with the Agencourt AMPure XP
reagent (Beckman Coulter, Brea, CA) and quantitated and
qualitatively assessed on the Agilent Bioanalyzer 2100.
A total of 500 ng of each size-selected fragment library
was hybridized with pooled solution-phase DNA probes
from the Ion TargetSeq™ Exome Enrichment Kit for
72 h, then the DNA was recovered, amplified, and puri-
fied according to the manufacturer’s instructions.
The enriched DNA was sequenced by the Ion Proton
sequencer according to the manufacturer’s protocols. Se-
quencing templates were prepared on Ion OneTouch 2
and Ion OneTouch ES stations, then loaded onto the
Proton PI Chip prior to sequencing.
SureSelect Human All Exon v4 exome enrichment and
HiSeq 2000 sequencing
A total of 1.5 μg of high-quality genomic DNA per sample
was used in the Agilent SureSelect Human All Exon v4 kit
capture process. Randomly fragmented DNA was end-
repaired, extended with an ‘A’ nucleotide at the 3’end,
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amplified according to the manufacturer’s protocol (Sure-
Select Target Enrichment for Illumina Multiplexed Se-
quencing version 1.5; Agilent Technologies, Los Angeles,
CA). Exome-containing adapter-ligated libraries were
hybridized with RNA baits for 24 h at 65 °C, and enriched
with streptavidin-conjugated magnetic beads (Dynabeads
MyOne Streptavidin T1; Invitrogen). Captured libraries
were amplified, and then purified with the Agencourt
AMPure XP reagent, then analysed with the Agilent Bioa-
nalyzer 2100 to evaluate the library quality. The qualified
exome-captured libraries were sequenced using HiSeq
2000 with the TruSeq PE Cluster kit v3 and TruSeq SBS
kit v3 according to the manufacturer’s protocol.
Proton data analysing with Torrent Suite software
For each Proton run, “Ion TargetSeq” was used as the
application type, human reference hg19 (UCSC version of
GRCh37 reference assembly) as the reference library and
“Ion-TargetSeq-Exome-50 Mb-hg19_revA.bed” as the tar-
get regions bed file. Bases were called by the Torrent Suite
base calling algorithm, and aligned to human reference
hg19 by the Torrent Mapping Alignment Program
(TMAP v3.4.1), then alignment metrics were also pro-
duced. The above base-calling and reference-aligning were
performed using the default parameters. The BAM file
was subsequently used to call the corresponding variants
by the Torrent Variant Caller (TVC3.6.2) plugin using a
standard workflow entitled “Germ Line - High Stringency”.
Burrows–Wheeler Aligner - Genome Analysis Toolkit
variant calling for Proton reads
The GRCh37 reference assembly integrating with the
1000 Genomes Project phase I analysis (human_g1k_v37
version) was downloaded from the Genome Analysis
Toolkit (GATK) Resource bundle (https://www.broad
institute.org/gatk/download/). In the target regions of two
exome-capturing kits, no differences are found between ref-
erences of human_g1k_v37 and hg19. Proton reads were
aligned to human_g1k_v37 using the Burrows-Wheeler
Aligner (bwa) software version 0.6.2 (http://bio-bwa.
sourceforge.net/) with single-end reads mode [45, 46]. Du-
plicate reads based on paired ends aligning to the same
start locations because of either optical or PCR artefacts
were marked and excluded from further analysis using
the MarkDuplicates module of Picard software version
1.70 (http://broadinstitute.github.io/picard/). GATK v2.5-2
was applied to re-calibrate the base quality score, realign
reads around known and novel sites of InDel polymor-
phisms, and perform SNP and InDel discovery and
genotyping using standard hard filtering parameters
according to GATK Best Practices recommendations
[47–49]. GATK was used to filter high quality InDels
by hard criteria: “QD< 2.0, ReadPosRankSum < -20.0FS > 200.0” and SNPs by hard criteria: “QD<2.0, MQ<40.0,
FS > 60.0, HaplotypeScore > 13.0, MQRankSum < -12.5,
ReadPosRankSum < -8.0”.
Variant calling pipelines for HiSeq 2000 reads
When HiSeq 2000 and Proton platforms were compared,
HiSeq 2000 reads were aligned to human_g1k_v37 using
bwa v0.6.2 with the paired-end reads mode. While compar-
ing different pipelines calling variants for HiSeq 2000, reads
were aligned to human_g1k_v37 using bwa v0.6.2 with the
single-end reads mode. BAM sorting, duplicate read mark-
ing, realignment, base quality recalibration, variant calling
and filtering were performed with the same parameters used
for the bwa-GATK variant calling pipeline in Proton reads.
Validation of variants by Sanger sequencing
From the four samples, 240 SNPs and 240 small InDels
were picked for variant validation by Sanger sequencing.
Amplicons of ~200 bp containing the variants were de-
signed using AssayDesigner software (SEQUENOM Inc.,
USA) with default parameters. PCR products were se-
quenced by Sanger chemistry using the 3730XL sequen-
cer. All variants were manually called. Heterozygous
InDels produce a complex signal on the chromatogram
displaying multiple heterozygous peaks similar to substi-
tution polymorphisms and a secondary peak correspond-
ing to the base in the alternate allele [50]. This complex
signal was applied to recognize heterozygous InDels.
Accession No. All exome sequencing data in this report
are available at the NCBI under accession SRP052890.Additional files
Additional file 1: Figure S1. The cumulative coverage proportion of
target regions in 4 samples. The proportion of target region for specific
cumulative coverage, was caculated and were showed at the coverage
from 0× to 200× in for sample S1 (A), sample S2 (B), sample S3 (C) and
sample S4 (D). (PNG 196 kb)
Additional file 2: Table S1. Ti/Tv ratios statistics for SNPs. (XLSX 9 kb)
Additional file 3: Figure S2. The occurence of homopolymer size of
1-bp InDels detected by TargetSeq-Proton and SureSelect-HiSeq in
sample 3. The length and kinds (poly-A, poly-T, poly-G and poly-C) of the
homopolymer, matching the genomic location of and identical to the
base of 1 bp insertions or deletions, was caculated. The homopolymers
with different size in the 33.6 Mb overlapping exonic regions were
counted for sample S3. (PNG 72 kb)
Additional file 4: Table S2. Comparison of calling variants between
TVC and bwa_GATK tools for reads produced by Proton. (XLSX 9 kb)
Additional file 5: Table S3. Comparison of concordant variants
between softwares for reads produced by HiSeq 2000. (XLSX 9 kb)
Additional file 6: Table S4. The distribution of GC content and length
for reads produced by Proton and HiSeq 2000. (XLSX 8 kb)
Additional file 7: Table S5. The statistics for detected 1-bp InDels in
homopolymer and non-homopolymer regions. (XLSX 8 kb)
Additional file 8: Figure S3. Percentage of reads containing InDels in
regions of homopolymers (homopolymer size ≥5) in TargetSeq-Proton
and SureSelect-HiSeq data in sample S3. (PNG 19 kb)
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